Floatz logo

Docetaxel

Brain Neoplasms

Providence Health & ServicesSmall moleculePhase 2Dormant
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Brain Neoplasms cohort.

Asset / SponsorPhaseRating
Nivolumab
InSightec
Phase 3BB
MOTEXAFIN GADOLINIUM HYDRATE
Phase 3BB
gw786034
National Cancer Institute (NCI)
Phase 2BB
5-ala
Constantinos Hadjipanayis
Phase 2B
VITAMIN D
University of Utah
Phase 2/3B

View all 26 →

Same molecule, other indications

Docetaxel is also rated in:

prostate neoplasmDormant
BBB
Indicative ·
73 / 100
View asset →
pancreatic adenocarcinomaDormant
BBB
Indicative ·
72 / 100
View asset →
cancer of unknown primary siteDormant
BBB
Indicative ·
72 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →